Systematic-Review-Drug-Efficiency-Dissertation-Sample-Work-Tutors-India
Idiopathic Pulmonary Fibrosis (IPF) as the name suggests is a progressive disorder with no known aetiology. It is characterised by the thickening of the alveoli due to scarring resulting in cough. It is known to primarily occur in older adults over 60 years of age. The findings of IPF have a known association of Usual Interstitial Pneumonia (UIP) (Raghu et al., 2011; Kawano-Dourado & Kairalla, 2013; Wells, 2013). It has been deemed that the prognosis is generally poor when UIP has been confirmed (King et al., 2001b). The median survival rate of IPF is 50%, typically around two years after diagnosis (Raghu et al., 2011; King et al., 2001b). Idiopathic Pulmonary Fibrosis (IPF) as the name suggests is a progressive disorder with no known aetiology. It is characterised by the thickening of the alveoli due to scarring resulting in cough. It is known to primarily occur in older adults over 60 years of age. The findings of IPF have a known association of Usual Interstitial Pneumonia (UIP) (Raghu et al., 2011; Kawano-Dourado & Kairalla, 2013; Wells, 2013). It has been deemed that the prognosis is generally poor when UIP has been confirmed (King et al., 2001b). The median survival rate of IPF is 50%, typically around two years after diagnosis (Raghu et al., 2011; King et al., 2001b).
for at least 8 weeks before randomisation 2 Huang et al 14 Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients percentage of predicted forced vital capacity (FVC) of at least Yes Patients were randomised to receive oral pirfenidone and acetylcysteine Patients were randomised to receive placebo and acetylcysteine 45%, percentage of predicted carbon monoxide diffusing capacity (DLCO) of at least 30%, and PaO2 of at least 50 mmHg when the patient is at rest and breathing 14 https://www.ncbi.nlm.nih.gov/pubmed/26496265 © 2017-2018 All Rights Reserved, No part of this document should be modified/used without prior consent Tutors India - Your trusted mentor since 2001 www.tutorindia.com I UK # +44-1143520021, info@tutorsindia.com Page 84 of 172
- Page 43 and 44: © 2017-2018 All Rights Reserved, N
- Page 45 and 46: studies and have exhibited that inc
- Page 47 and 48: Numerous physiologic parameters lik
- Page 49 and 50: Dense fibrosis and honeycombing is
- Page 51 and 52: Pharmacological treatment: Glucocor
- Page 53 and 54: i. Oxygen Therapy and ventilation I
- Page 55 and 56: Numerous patients with IPF acquirin
- Page 57 and 58: should be undergone to reveal wheth
- Page 59 and 60: CHAPTER III: RESEARCH METHODOLOGY T
- Page 61 and 62: 3.2 Meta-analysis of Randomised Con
- Page 63 and 64: 3.4.1 Inclusion criteria The inclus
- Page 65 and 66: 3.6.1 Dichotomous Comparisons The v
- Page 67 and 68: CHAPTER IV: RESULTS 4.1 Introductio
- Page 69 and 70: Following are the questions of the
- Page 71: Study number Table 2- CASP assessme
- Page 75: primary objective is to examined wh
- Page 79: to NAC inhaled inhaled NAC and oral
- Page 82: S. no Author; Year 1 Behr et al 7 C
- Page 86: pirfenidone combined with highdose
- Page 90: or temporary cessation of pirfenido
- Page 93: 4.5 Patient characteristics, interv
- Page 99: © 2017-2018 All Rights Reserved, N
- Page 102 and 103: © 2017-2018 All Rights Reserved, N
- Page 105: 6 min walk the distinct possibility
- Page 109: percentage predicted FEV1, total lu
- Page 113: (DLco) of almost 43% of the predict
- Page 116 and 117: 4.7 Assessment of likelihood of com
- Page 118 and 119: espectively. However, one study by
- Page 120 and 121: the combined effects of these drugs
- Page 122 and 123: Pirfenidone, which is a proven ther
- Page 124 and 125: with respect to background factors
- Page 126 and 127: patient in the intervention group a
- Page 128 and 129: and N-acetylcysteine when combined
- Page 130 and 131: References Abehsera, M., Valeyre, D
- Page 132 and 133: from: http://www.ncbi.nlm.nih.gov/p
- Page 134 and 135: worsening of idiopathic pulmonary f
- Page 136 and 137: (6). pp. 515-20. Available from: ht
- Page 138 and 139: http://www.ncbi.nlm.nih.gov/pubmed/
- Page 140 and 141: Hunninghake, G.W., Colby, T. V., Eg
- Page 142 and 143: Diaz de Leon, A., Cronkhite, J.T.,
for at least 8<br />
weeks<br />
before<br />
randomisation<br />
2<br />
Huang et al 14<br />
Double-Blind Randomized Trial<br />
of Pirfenidone in Chinese<br />
Idiopathic Pulmonary Fibrosis<br />
Patients<br />
percentage of<br />
predicted forced<br />
vital capacity<br />
(FVC) of at least<br />
Yes<br />
Patients were randomised<br />
to receive oral pirfenidone<br />
and acetylcysteine<br />
Patients were<br />
randomised to<br />
receive placebo<br />
and acetylcysteine<br />
45%, percentage<br />
of<br />
predicted<br />
carbon monoxide<br />
diffusing capacity<br />
(DLCO) of at<br />
least 30%, and<br />
PaO2 of at least<br />
50 mmHg when<br />
the patient is at<br />
rest and breathing<br />
14 https://www.ncbi.nlm.nih.gov/pubmed/26496265<br />
© 2017-2018 All Rights Reserved, No part of this document should be modified/used without prior consent<br />
<strong>Tutors</strong> <strong>India</strong> - Your trusted mentor since 2001<br />
www.tutorindia.com I UK # +44-1143520021, info@tutorsindia.com<br />
Page 84 of 172
Change language